US-based biopharmaceutical company AbbVie (NYSE: ABBV) announced on Monday that 27 abstracts across its gastroenterology portfolio will be presented at the Digestive Disease Week (DDW) Annual Meeting, 21-24 May 2022, in San Diego and virtually.

AbbVie's research to be presented at DDW 2022 addresses digestive and inflammatory bowel diseases, including ulcerative colitis (UC), Crohn's disease (CD), and irritable bowel syndrome with constipation (IBS-C)/chronic idiopathic constipation (CIC).

'Since establishing our commitment to gastroenterology 15 years ago, our presence at DDW has grown continuously as our portfolio has expanded,' said Celine Goldberger M.D., Ph.D., vice president, head of US medical affairs, AbbVie. 'We are proud to present data on a range of digestive conditions across our portfolio and pipeline. AbbVie's commitment to GI and IBD patients remains strong, and we are looking forward to connecting again with the gastroenterology community at DDW this year.'